At the news
? BULLISHIMPACT 7/10 8-K filed May 12, 2026 at 07:07 ET
Alkermes announced positive topline results from the REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia (IH), meeting all primary and key secondary endpoints with high statistical significance (p<0.0001). The company plans to file an sNDA with the FDA by end of 2026, but a prior settlement agreement bars marketing LUMRYZ for IH before March 1, 2028, even if approved. This is a clear clinical win that expands LUMRYZ's addressable market into a rare disease affecting ~40,000 U.S. patients, though commercial upside is delayed by the marketing restriction.
- LUMRYZ met the primary endpoint (ESS, p<0.0001) and all key secondary endpoints (PGI-C, IHSS, both p<0.0001) in the REVITALYZ Phase 3 study for idiopathic hypersomnia.
- Safety profile consistent with known LUMRYZ data; no new safety signals observed.
- Alkermes plans to file a supplemental New Drug Application (sNDA) with the FDA by the end of 2026.
- A prior settlement and license agreement prohibits marketing LUMRYZ for IH before March 1, 2028, even if FDA approval is granted earlier.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access